Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Silo Pharma Inc

Healthcare US SILO

5.9USD
-0.21(3.44%)

Last update at 2026-06-05T20:00:00Z

Day Range

5.756.23
LowHigh

52 Week Range

1.223.98
LowHigh

Fundamentals

  • Previous Close 6.11
  • Market Cap4.95M
  • Volume25236
  • P/E Ratio-
  • Dividend Yield-%
  • Revenue TTM0.07M
  • Revenue Per Share TTM0.02
  • Gross Profit TTM 0.07M
  • Diluted EPS TTM-1.4

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -3.90739M 4.18M -3.03752M -1.01329M -0.96946M
Minority interest - - - - -
Net income -3.90855M 3.90M -3.12987M -1.04809M -0.96946M
Selling general administrative 2.43M 2.27M 2.18M 0.86M 0.46M
Selling and marketing expenses -1.26943M - - - -
Gross profit 0.07M 0.07M -0.13520M 0.01M -
Reconciled depreciation - - - 0.00000M 0.02M
Ebit -3.64766M -2.74434M -2.57297M -0.93040M 0.05M
Ebitda -3.57502M -2.89163M -2.39305M -0.90227M 0.07M
Depreciation and amortization 0.07M -0.14729M 0.18M 0.03M 0.02M
Non operating income net other - - - - -
Operating income -3.64766M -2.74434M -2.57297M -0.93040M -0.59424M
Other operating expenses 3.72M 2.96M 2.45M 0.96M 0.46M
Interest expense 0.00220M 0.00304M 0.27M 0.06M 0.00422M
Tax provision 0.00000M 0.02M - - -
Interest income 0.07M 0.00121M 0.01M 0.01M 0.00422M
Net interest income 0.07M -0.00183M -0.25772M -0.05073M 0.00422M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.00116M 0.02M 0.09M 0.03M -0.51385M
Total revenue 0.07M 0.07M 0.04M 0.04M 0.00000M
Total operating expenses 3.71M 2.96M 2.27M 0.93M 0.46M
Cost of revenue 0.00584M 0.00500M 0.18M 0.03M -
Total other income expense net -0.25973M 6.93M -0.46455M -0.08289M -0.51385M
Discontinued operations - -0.25337M -0.37125M -0.37125M -0.37125M
Net income from continuing ops -3.90739M 4.16M -3.03752M -1.01329M -0.96946M
Net income applicable to common shares - 2.50M -3.10652M -1.01329M -0.96946M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 11.64M 10.49M 1.43M 0.49M 0.86M
Intangible assets - - - - 0.03M
Earning assets - - - - -
Other current assets 0.14M 0.15M 0.24M 0.02M 0.03M
Total liab 1.30M 1.43M 0.15M 0.52M 0.45M
Total stockholder equity 10.34M 9.06M 1.28M -0.02289M 0.41M
Deferred long term liab 0.06M 0.02M - - -
Other current liab 0.36M 0.42M 0.14M 0.12M 0.03M
Common stock 0.00032M 0.00986M 0.00851M 0.00236M 0.00234M
Capital stock 0.00032M 0.00986M 0.00851M 0.00236M 0.00234M
Retained earnings -7.17113M -3.26258M -5.76232M -2.65580M -1.64251M
Other liab - 0.94M - - -
Good will - - - - -
Other assets - 0.09M - - 0.20M
Cash 11.37M 9.84M 1.13M 0.11M 0.34M
Cash and equivalents - - - - -
Total current liabilities 0.44M 0.49M 0.14M 0.12M 0.05M
Current deferred revenue 0.07M 0.07M -0.14172M -0.11674M -
Net debt -11.36703M -9.83700M -1.10949M -0.04988M -0.31433M
Short term debt -0.36422M -0.41794M 0.01M 0.06M 0.02M
Short long term debt - - 0.01M 0.06M 0.02M
Short long term debt total - - 0.02M 0.06M 0.02M
Other stockholder equity 17.51M 12.31M 7.03M 2.63M 2.05M
Property plant equipment - - - - -
Total current assets 11.57M 10.40M 1.43M 0.49M 0.63M
Long term investments - - - - -
Net tangible assets - 9.06M 1.28M -0.02289M 0.38M
Short term investments 0.00312M 0.42M 0.00020M 0.00939M 0.23M
Net receivables 0.07M 0.06M 0.02M 0.20M -
Long term debt - - 0.00425M - -
Inventory - -0.06121M 0.03M 0.16M 0.03M
Accounts payable 0.36M 0.42M 0.13M 0.05M 0.03M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - -0.40000M -0.40000M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.07M 0.09M - - 0.20M
Deferred long term asset charges - - - - -
Non current assets total 0.07M 0.09M 0.00000M 0.00000M 0.23M
Capital lease obligations - - - - -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 0.09M 7.02M 7.02M 0.19M 0.19M
Change to liabilities - 0.77M 0.07M 0.03M -0.01271M
Total cashflows from investing activities - 7.19M 0.04M 0.19M -0.25000M
Net borrowings - - 0.02M 0.27M -0.00218M
Total cash from financing activities 4.94M 3.79M 2.13M 0.38M 0.02M
Change to operating activities - -0.04007M -0.14466M 0.02M 0.02M
Net income -3.90855M 3.90M -3.03752M -1.01329M -0.96946M
Change in cash 1.53M 8.71M 1.02M -0.22493M 0.04M
Begin period cash flow 9.84M 1.13M 0.11M 0.34M 0.29M
End period cash flow 11.37M 9.84M 1.13M 0.11M 0.34M
Total cash from operating activities -3.49762M -2.27802M -1.15700M -0.79432M 0.27M
Issuance of capital stock 4.94M 3.79M 2.12M 0.11M 0.02M
Depreciation - 0.11M 0.58M 0.06M 0.02M
Other cashflows from investing activities - 0.17M 0.04M 0.04M -0.25000M
Dividends paid - - - - 0.00218M
Change to inventory - - -0.01507M -0.12939M -0.02697M
Change to account receivables - - -0.07253M -0.02923M -
Sale purchase of stock - - - 0.00000M -0.00287M
Other cashflows from financing activities 0.09M 7.19M 0.05M 0.32M 0.00218M
Change to netincome - -6.91147M 1.68M 0.24M 1.24M
Capital expenditures 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.07529M 0.73M -0.08720M -0.08246M -0.01680M
Stock based compensation 0.16M 0.19M 1.19M 0.18M -
Other non cash items 0.33M -7.10317M 0.78M 0.12M 1.24M
Free cash flow -3.49762M -2.27802M -1.15700M -0.79432M 0.27M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
SILO
Silo Pharma Inc		 -0.21 3.44% 5.90 - - 67.51 0.64 68.66 0.93
NVO
Novo Nordisk A/S		 -0.79 1.81% 42.96 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.6937 1.57% 43.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 5.09 1.15% 446.83 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.72 1.07% 635.45 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Silo Pharma. Inc., a developmental stage biopharmaceutical company, focuses on merging traditional therapeutics with psychedelic research. The company's developing solutions to address various underserved conditions. It also seeks to acquire and/or develop intellectual property or technology rights from universities and researchers to treat rare diseases, including the use of psychedelic drugs, such as psilocybin, and the benefits they may have in certain cases involving depression, mental health issues, and neurological disorders. The company focuses on merging traditional therapeutics with psychedelic research for people suffering from indications, such as depression, post-traumatic stress disorder, Alzheimer's, Parkinson's, and other rare neurological disorders. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is headquartered in Englewood Cliffs, New Jersey.

Silo Pharma Inc

560 Sylvan Avenue, Englewood Cliffs, NJ, United States, 07632

Key Executives

Name Title Year Born
Mr. Eric Weisblum Chairman, Pres & CEO 1970
Mr. Daniel E. Ryweck Chief Financial Officer 1965
Dr. James S. Kuo M.B.A., M.D. VP of R&D 1965

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions